Sandoz公司收购了Evotec的图卢兹工地和J.POD技术公司,以促进生物相似物的生产,交易于2025年12月5日结束。 Sandoz acquires Evotec’s Toulouse site and J.POD tech to boost biosimilars production, with deal closing Dec. 5, 2025.

2025年12月5日起,桑多斯获得Evotec的图卢兹制造厂址,并获得其J.POD连续制造技术的无限期许可证,以加强其生物类生产能力。 Sandoz has acquired Evotec’s Toulouse manufacturing site and an indefinite license to its J.POD continuous manufacturing technology, effective December 5, 2025, to strengthen its biosimilars production capabilities. 这笔交易提高了Sandoz的内部发展和制造业效率,但不影响其2025年财务指南。 The deal enhances Sandoz’s in-house development and manufacturing efficiency without impacting its 2025 financial guidance. Evotec完成销售,转向较轻、资产效率高的模式,收取预付费和潜在未来付款超过6.5亿美元,包括多达10个生物类的里程碑和特许权使用费,其销售额超过900亿美元。 Evotec completed the sale to shift toward a lighter, asset-efficient model, receiving upfront fees and potential future payments exceeding $650 million, including milestones and royalties on up to ten biosimilars targeting over $90 billion in originator sales. 这项交易是立即增加收入的,支持Evotec将重点放在毒品发现和生物生物学发展上,同时继续提供全球制造服务,并通过发放许可证扩大获得技术的机会。 The transaction is immediately earnings accretive and supports Evotec’s focus on drug discovery and biologics development, while it continues providing global manufacturing services and expanding access to its technology through licensing.